Warning to buyers: non-disclosure of FDA warning letters in due diligence did not trigger sellers’ liability
Insufficient substantiation of claims by the buyer of shares of a homeopathic drugs company for damages caused by an alleged breach of contractual warranty (non-disclosure of FDA warning letters) in a share purchase agreement.